首页 News 正文

On December 7th, Abbey and Cerevel Therapeutics announced a final agreement - Abbey will acquire Cerevel Therapeutics and its neuroscience pipeline. Cerevel's pipeline consists of multiple clinical stages and preclinical candidate drugs developed to treat diseases such as schizophrenia, Parkinson's disease (PD), and mood disorders.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

tengxiao 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    0